Bristol, Pfizer anti-clot drug hits goals in trial

(Reuters) - Patients treated with apixaban, a pill, had comparable
rates in two main measures to those on the standard of care --
an injected therapy plus one drug from the class that includes
the widely used warfarin. The measures included rates of blood
clots and dangerous bleedings.




Though effective at alleviating clotting, many
anticoagulant therapies come with serious drawbacks. Heparin
drugs must be injected or given intravenously, and warfarin is
notoriously difficult to regulate properly because of its
interactions with food and other medicines.


Read more at Reuters.com Government Filings News